SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogelon Mars

Dogelon Mars continues to trend on social platforms as the community maintains high engagement through persistent speculation on future utility and potential price catalysts. While some investors remain skeptical due to long-term performance, others are actively tracking market developments and comparing the project against broader meme coin trends in anticipation of a breakout.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is trending as the community debates its long-term potential as a key infrastructure player in the decentralized AI and autonomous agent sector. Investors are closely watching critical resistance levels and recent ecosystem developments while weighing the impact of broader crypto market fluctuations on the token's recovery.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is currently generating significant community buzz as investors weigh its potential for a short squeeze against concerns over recent insider selling and weak financial performance. Market participants are actively debating the company's future, with many pointing to its critical government contracts and the potential for strategic mergers as key catalysts that could drive a reversal for this long-suffering stock.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is facing a significant sell-off as investors react to management pulling long-term targets and issuing cautious guidance, fueling concerns about AI-driven disruption in the software sector. While the community remains polarized over whether this is a deep-value buying opportunity or a structural decline, many are actively debating the company's ability to maintain its growth trajectory amidst intensifying competition.

Virgin Galactic Holdings, Inc. is an aerospace and space travel company, which engages in the provision of consumer space experience using reusable spaceflight systems. The firm is also involved in designing, developing, and manufacturing, ground and flight testing, spaceflight operation, and post-flight maintenance of spaceflight systems. The company was founded on May 5, 2017 and is headquartered in Tustin, CA.

Virgin Galactic Holdings Inc - Ordinary Shares - Class A

Virgin Galactic Holdings Inc

Virgin Galactic is experiencing a massive surge in retail interest and social media volume, driven by speculation surrounding the upcoming SpaceX IPO and potential short-squeeze dynamics. The community remains deeply polarized, with bulls highlighting the company's progress toward commercial flight and growth potential in the space sector, while skeptics warn of volatility, past financial struggles, and the risk of being a short-term meme play.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian is experiencing intense market volatility and significant bearish sentiment following its removal from the Nasdaq-100, fueling community debates on whether the stock is a deep-value turnaround opportunity or facing structural obsolescence due to AI agents. Investors remain sharply divided, with bulls pointing to the continued enterprise reliance on Jira and Confluence as a resilient moat, while bears argue that agentic AI and shifting IT spending are permanently eroding the company's SaaS business model.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently trending as investors focus on its potential as a quantum-resistant blockchain, with community sentiment shifting toward optimism following recent technical mentions. Traders are actively debating whether this movement represents a sustainable trend or another cycle of volatility, with many users focused on accumulating positions for long-term growth.

JetBlue Airways Corp. engages in the provision of air transportation services. Its brands include jetBlue, jetBlue Vacations, Paisly, and TrueBlue. It operates through the following geographic segments: Domestic and Canada, Caribbean and Latin America, and Atlantic. The company was founded by David Gary Neeleman in August 1998 and is headquartered in Long Island City, NY.

Jetblue Airways Corp

JetBlue is trending as investors react to reports that the airline is exploring potential merger or sale options, with the community actively speculating on the likelihood of a strategic acquisition by a larger carrier. While bullish sentiment is fueled by buyout rumors and recent operational expansion, concerns remain regarding the company's debt levels and the broader impact of rising fuel costs on the airline sector.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as investors focus on the pivotal upcoming FDA decision for ivonescimab, with community members actively discussing the potential of its clinical data to challenge established cancer therapies. While the stock has faced recent volatility and bearish analyst sentiment, long-term investors remain highly convicted, viewing the company's aggressive clinical pipeline and institutional backing as key drivers for future growth.

Photronics, Inc. engages in the provision of photomasks, which are quartz or glass plates containing microscopic images of electronic circuits for use in the fabrication of integrated circuits and flat-panel displays. The company was founded by Constantine S. Macricostas in 1969 and is headquartered in Brookfield, CT.

Photronics, Inc.

Photronics is currently in focus as investors analyze the impact of delayed industry design cycles and cautious management guidance on its near-term growth trajectory. While the community remains divided over its low valuation and cash-rich balance sheet, many are actively debating whether current support levels offer an attractive entry point for a long-term recovery.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade

Johnson & Johnson (JNJ) reached $225.33 at the closing of the latest trading day, reflecting a -2.37% change compared to its last close.

JNJ Reports Promising Survival Data From CHRYSALIS-2 Lung Cancer Study

Equity

New study results highlight the potential of JNJ's RYBREVANT-LAZCLUZE combination to improve long-term outcomes in EGFR-mutated lung cancer.

RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment...

New TECVAYLI (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

New TECVAYLI (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma New TECVAYLI (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma PR Newswire...

FDA approves label expansion, cementing TREMFYA as the only IL23 inhibitor proven to help stop further joint damage

FDA approves label expansion, cementing TREMFYA as the only IL23 inhibitor proven to help stop further joint damage FDA approves label expansion, cementing TREMFYA as the only IL23 inhibitor proven to help stop further joint damage PR Newswire HORSHAM, Pa., May 28, 2026 TREMFYA showed significant...

Is Johnson & Johnson (JNJ) a Buy as Wall Street Analysts Look Optimistic?

The average brokerage recommendation (ABR) for Johnson & Johnson (JNJ) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

J&J Stock Gains Nearly 12% Year to Date: Buy, Sell or Hold Now?

JNJ is up nearly 12% YTD as strong oncology drug growth, MedTech demand and pipeline advances help offset Stelara patent-loss pressure.

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 15th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Ryan Koors...

BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst

Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus.

Black Diamond Stock Outlook After Q1 Beat and Cash Runway

BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profile and pivotal path.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$2.85	--	--	N/A
Q1 '26	$2.68	$2.70	0.85%	BEAT
Q4 '25	$2.46	$2.46	-0.12%	MISSED
Q3 '25	$2.76	$2.80	1.54%	BEAT
Q2 '25	$2.68	$2.77	3.29%	BEAT

JNJ
Johnson & Johnson

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Compact View

Latest JNJ News

JNJJohnson & Johnson